Gt biopharma to be added to the russell 2000® index

Beverly hills, calif., june 8, 2021 /prnewswire/ -- gt biopharma, inc. ("gt biopharma" or the "company") (nasdaq: gtbp), a clinical stage immuno-oncology company focused on developing innovative therapeutics based on the company's proprietary natural killer (nk) cell engager (trike™) protein biologic technology platform, today announced that it is set to be added to the russell 2000® index at the conclusion of the russell us indexes annual reconstitution, effective at the opening of the u.s. equity markets on june 28, 2021.
GTBP Ratings Summary
GTBP Quant Ranking